** Shares of drug developer Rapt Therapeutics RAPT.O fall 42.4% to $1.66

** Co says based on recent feedback from the U.S. FDA it has stopped development of its drug Zelnecirnon, for eczema and asthma

** The decision follows a clinical hold placed on the drug's trial by the FDA in February after a serious case of liver injury in one of the patients

** Co says it will identify a new experimental therapy to develop in H1 2025

** Including session's move, stock down 93.4%

(Reporting by Puyaan Singh and Christy Santhosh)

((Puyaan.Singh@thomsonreuters.com))